Loading...
•
Jun 30, 2021
Paysign Q2 2021 Earnings Report
Paysign's Q2 2021 financial results showed sequential improvement in revenues and operating results, driven by easing pandemic-related stimulus and diversification efforts.
Key Takeaways
Paysign reported improved revenues and operating results for Q2 2021, benefiting from the phasing out of pandemic-related stimulus. The company is focused on diversifying its business and investing in long-term growth, with the renewal of a major pharmaceutical hub customer and the addition of five new pharmaceutical copay programs expected to launch between now and the end of 2021.
Saw month-over-month improvements in financial results as pandemic-related stimulus began to phase out.
Continued to focus on diversifying business and investing for sustained long-term growth.
Renewed a major pharmaceutical hub customer and their copay programs.
Added five new pharmaceutical copay programs that are expected to launch between now and the end of 2021.
Paysign
Paysign
Forward Guidance
Paysign forecasts continued revenue growth and improved profitability for 2021, contingent on the absence of widespread lockdowns and additional government stimulus. The company anticipates benefiting from the end of unemployment subsidies in early September.
Positive Outlook
- Total revenue to be in the range of $29.0 million to $32.0 million, reflecting growth of 20% to 32%.
- Adjusted EBITDA forecast to be in the range of $0.75 million to $1.90 million due to the better-than-expected results this quarter and higher gross profit margin expectations.
- Gross profit margin forecast raised by 150 basis points to 46.5%, an increase of 790 basis points over 2020.
- Improving trends will continue as long as the U.S. does not enter widespread lockdown conditions.
- Business will benefit in the fourth quarter as unemployment subsidies for the entire country are scheduled to end in early September.
Challenges Ahead
- Second quarter continued to be impacted by COVID-19 and government stimulus measures as expected.
- The COVID-19 outbreak and the new stimulus packages signed into law during 2020 and 2021 have had and will continue to have an adverse effect on the company's results of operations.
- Uncertainty around the extent and timing of the potential future spread or mitigation of COVID-19 and variants.
- Management cannot reasonably estimate the impact on the company's future results of operations, cash flows or financial condition.
- Operating expenses are expected to increase modestly between $18.0 million to $18.5 million, or 2.0% to 4.9%.